WO2010059366A2 - Antimicrobial foamable soaps - Google Patents

Antimicrobial foamable soaps Download PDF

Info

Publication number
WO2010059366A2
WO2010059366A2 PCT/US2009/062527 US2009062527W WO2010059366A2 WO 2010059366 A2 WO2010059366 A2 WO 2010059366A2 US 2009062527 W US2009062527 W US 2009062527W WO 2010059366 A2 WO2010059366 A2 WO 2010059366A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
surfactant
antimicrobial
mrsa
foamable
Prior art date
Application number
PCT/US2009/062527
Other languages
English (en)
French (fr)
Other versions
WO2010059366A3 (en
Inventor
M. D. Larry Weiss
Original Assignee
Ohso Clean, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2009317951A priority Critical patent/AU2009317951B2/en
Application filed by Ohso Clean, Inc. filed Critical Ohso Clean, Inc.
Priority to KR1020117011873A priority patent/KR101757935B1/ko
Priority to US13/126,628 priority patent/US20110206790A1/en
Priority to MX2011004539A priority patent/MX2011004539A/es
Priority to EP09827969.8A priority patent/EP2350252A4/en
Priority to CA2742285A priority patent/CA2742285A1/en
Priority to BRPI0920972A priority patent/BRPI0920972A8/pt
Priority to JP2011534753A priority patent/JP5782603B2/ja
Priority to CN2009801537618A priority patent/CN102317429A/zh
Publication of WO2010059366A2 publication Critical patent/WO2010059366A2/en
Publication of WO2010059366A3 publication Critical patent/WO2010059366A3/en
Priority to ZA2011/03129A priority patent/ZA201103129B/en
Priority to IL212612A priority patent/IL212612A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/382—Vegetable products, e.g. soya meal, wood flour, sawdust
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D9/00—Compositions of detergents based essentially on soap
    • C11D9/005—Synthetic soaps
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16—Heavy metals; Compounds thereof
    • A01N59/20—Copper
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08—Magnoliopsida [dicotyledons]
    • A01N65/22—Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/02—Inorganic compounds ; Elemental compounds
    • C11D3/04—Water-soluble compounds
    • C11D3/046—Salts
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/168—Organometallic compounds or orgometallic complexes
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D9/00—Compositions of detergents based essentially on soap
    • C11D9/04—Compositions of detergents based essentially on soap containing compounding ingredients other than soaps
    • C11D9/22—Organic compounds, e.g. vitamins
    • C11D9/38—Products in which the composition is not well defined

Definitions

  • the invention generally relates to antimicrobial foamable compositions for the treatment and prevention of skin infections. More particularly, the invention relates to topical antimicrobial foamable compositions containing thyme oil for the treatment and prevention of bacterial infections and drug-resistant bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA).
  • MRSA methicillin-resistant Staphylococcus aureus
  • Staphylococcus aureus is a bacterial strain that is found normally on the skin or in the nose of roughly one third of the population. Staph infections are one of the most common causes of skin infections in the United States. Most Staph infections are minor and can be treated with antibiotics. However, Staph can also cause serious infections of the skin and soft tissue, bloodstream infections, and pneumonia.
  • MRSA Methicillin-resistant Staphylococcus aureus
  • HA- MRSA healthcare-associated MRSA
  • CA- MRSA community-associated MRSA
  • a green and environmentally- friendly antimicrobial foamable composition is provided herein.
  • the principal or sole antimicrobial agent in the foamable composition is thyme oil.
  • the antimicrobial foamable compositions described herein provide many advantages over conventionally available antimicrobial foams employing synthetic and semi-synthetic antimicrobial compounds, including non-toxicity to individuals, fewer adverse side effects, increased efficacy, particularly against MRSA, and a lower incidence of failure thereby causing fewer resistant infections as a result of treatment.
  • the invention provides a green and environmentally antimicrobial foamable composition for killing MRSA on a surface contaminated therewith, and methods for killing MRSA on a surface contaminated therewith.
  • the invention may be implemented in a number of ways.
  • the foamable composition comprises an antimicrobial amount of thyme oil of about 0.01% w/v to about 0.5% w/v, a surfactant and a source of divalent copper ions.
  • the composition kills greater than 99.9% or greater than 99.99% of MRSA in 15 seconds when applied to the contaminated surface.
  • the composition contains about 0.01% w/v to about 0.2% w/v of thyme oil.
  • a copper peptide complex such as copper PCA, may be the source of the divalent copper ion.
  • the surfactant may include anionic or nonionic surfactants, which may be selected from the non-limiting group of alkyl polyglucoside surfactants, sodium lauryl sulfate, and sodium laureth sulfate. Particular efficacy is associated with the use of an alkyl polyglucoside surfactant, which may be either an anionic or nonionic surfactant.
  • the surfactant is a biobased surfactant, which is a surfactant that is not principally derived from a petrochemical feedstock.
  • the foamable composition may also contain, in addition to thyme oil, origanum oil, which may be present in an amount of about 0.01% w/v to about 0.2% w/v. In addition, the composition may further contain thymol crystals, which may be present in an amount of about 0.01% w/v to about 0.05% w/v.
  • the foamable composition may further contain at least one fragrance, which may be selected from the non- limiting group of blood orange, vanilla, lavender, ginger, bergamot, spearmint, and lime.
  • the composition may also contain an antioxidant, such as white tea extract.
  • the topical foamable composition for killing MRSA on a surface contaminated therewith comprises 0.016% w/v thyme oil, 0.016% w/v origanum oil, 0.032% w/v botanical thymol crystals, 3.0% v/v alkyl polyglucoside surfactant, 0.008% w/v copper PCA, and water to 100%.
  • the composition kills greater than 99.9% or greater than 99.99% of MRSA in 15 seconds when applied to the contaminated surface.
  • the composition may further comprise one or more components selected from white tea, citric acid, sodium citrate, co-surfactant, natural moisturizer, and aloe vera.
  • a method for killing MRSA on a surface contaminated therewith includes applying to the surface a foamable composition comprising an antimicrobial amount of thyme oil of about 0.01% w/v to about 0.5% w/v, a surfactant and a source of divalent copper ions. Further, the method includes exposing the surface to the composition for an exposure time sufficient to kill MRSA.
  • the surface may be mammalian skin, in particular human skin.
  • the composition may be applied to an open wound.
  • the composition may be applied for an exposure time of, for example, at least 15 seconds, at least 5 minutes, or at least an hour.
  • the composition may be applied at least once a day.
  • the composition kills greater than 99.9% or greater than 99.99% of MRSA in 15 seconds.
  • a kit comprises an antimicrobial foamable composition for killing MRSA on a surface contaminated therewith, the composition comprising an antimicrobial amount of thyme oil of about 0.01% w/v to about 0.5% w/v, a surfactant and a source of divalent copper ions. Further, the kit comprises a dispenser.
  • the foamable compositions described herein are environmentally friendly and green compositions for killing MRSA on a contaminated surface.
  • the foamable compositions employ a low concentration of thyme oil as the principal or sole antimicrobial agent, a surfactant and a source of divalent copper ions.
  • the foams may be used to prevent or treat skin infections, in particular MRSA infections. Symptoms of a skin infection can include lesions, sores, rashes, blisters, abscesses, or cracking of the skin, all of which can by accompanied by discoloration, inflammation, swelling, or pain.
  • the foams may treat infections by reducing the duration of the symptoms, reducing the severity of the symptoms, or both. Additionally, the foams may cure the infection and/or eliminate the symptoms of the infection.
  • the terms "foamable” and “foam” refer to a substance that is made by forming and trapping gas bubbles in a liquid.
  • a foam may be formed by injecting air into a liquid foamable composition and trapping the air.
  • a foam can be formed by dispensing the antimicrobial compositions described herein from a container (e.g., bottle or pump) such that the composition is mixed with gas bubbles, and the bubbles are trapped in the composition.
  • Conventional devices for generating a foam from a liquid can be employed with the compositions and methods of the present invention.
  • natural and “botanical” refer to substances that are derived, either whole or in part, from natural (e.g., plant) sources. These substances have minimal environmental impact and require minimal non-renewable inputs when the entire life cycle of the substance is considered.
  • an "all-natural” substance is obtained from a botanical source or with the aid of biological processes.
  • natural thymol refers to thymol obtained from a plant
  • synthetic thymol refers to thymol that is chemically synthesized from petroleum.
  • the foamable compositions described herein can contain "all-natural", “botanical” products.
  • All-natural does not exclude various separation processes such as extraction, distilling, etc. or minimal synthetic (i.e., semisynthetic) transfo ⁇ nations of natural products. It is intended to exclude products that have been solely chemically created by man.
  • the products within the scope of the invention are preferably natural based products.
  • the term “environmentally friendly” is used to refer to compounds and products designed to inflict minimal harm on the environment. "Environmentally- friendly” ingredients and chemicals may be used in place of standard products containing chemically-reactive and toxic compounds to avoid or minimize the adverse effects on the environment.
  • the term “green” is used to refer to compounds and products that minimize human illnesses as well as minimize damage to the environment as a result of exposure to the compound or product. The EPA has provided principles directed to green chemistry, which include (i) the design of safer chemicals and products that are fully effective, yet have little or no toxicity, and (ii) the design of less hazardous chemical syntheses. Both of these principles apply to the current invention.
  • the term “green” also includes naturally-derived products, such as the thyme oil of the present invention, that have undergone little chemical modification or no chemical modification. Thus, the foamable compositions described herein are "environmentally friendly,” “green” products.
  • antimicrobial refers to a substance that kills or inhibits the growth of microbes such as bacteria, mycobacteria, parasites, fungi, yeast, viruses, or other microscopic organisms.
  • An antimicrobial substance may be a microbistatic or microbicidal agent.
  • microbistatic means to slow or prevent the growth of microbes.
  • a microbistatic substance may interfere with protein production, DNA replication, cellular metabolism, etc.
  • microbicidal means to kill microbes.
  • the antimicrobial foamable compositions described herein may be used to kill or inhibit bacteria, mycobacteria, parasites, fungi, yeast, viruses, or other microscopic organisms.
  • the foamable compositions of the invention are particularly adapted to be microbicidal with respect to MRSA.
  • an antimicrobial amount refers to an amount of a substance that inhibits the growth of or kills bacteria, mycobacteria, parasites, fungi, yeast, or viruses.
  • an antimicrobial amount of thyme oil is an amount of thyme oil capable of inhibiting or killing bacteria, particularly MRSA, mycobacteria, parasites, fungi, yeast, or viruses.
  • antibacterial refers to a substance that inhibits bacterial growth (“bacteriostatic”) or kills bacteria (“bacteriocidal”).
  • antibiotic and antibiotic amount refers to a substance or an amount, respectively, that inhibits bacterial growth, inhibits bacterial virulence, or kills bacteria.
  • Antibiotics include natural, synthetic, or semi-synthetic compounds.
  • the foamable compositions described herein may be used as an antibacterial agent effective against one or more bacterial strains including, but not limited to, Staphylococcus, such as MRSA, Streptococcus, Pseudomonas, Helicobacter, Salmonella, and Enterococcus.
  • antifungal refers to a substance that inhibits fungal growth and/or replication ("fungistatic") or kills fungi (“fungicial”). Examples of fungi include Trichophyton, Microsporum, and Epidermophyton.
  • the term “antifungal” is an FDA regulated term defined as a drug that inhibits the growth and reproduction of fungal cells and decreases the number of fungi present.
  • the term "fungus” as used herein is defined according to the FDA definition of any of a large division of plants, including dermatophytes, yeasts, and molds, characterized by a simple cell structure and the absence of chlorophyll. Fungal infections can cause skin disorders such as jock itch, ring worm, and athlete's foot.
  • antiviral refers to a substance that inhibits viral growth and/or replication (“virustatic”) or kills viruses (“virucidal”).
  • the foamable composition may be used as at least one of a microbistatic, microbicidal, bacteriostatic, bacteriocidal, fungistatic, fungicidal, virustatic, and virucidal substance.
  • a microbistatic, microbicidal, bacteriostatic, bacteriocidal, fungistatic, fungicidal, virustatic, and virucidal substance Specifically, embodiments of the foamable composition have demonstrated high bactericidal efficacy. More specifically, the foamable composition are remarkably effective against drug-resistant bacteria, including several strains of MRSA. Efficacy (i.e., the kill rate) was determined by measuring the percent reduction of MRSA bacteria at a given time following application of the foamable composition to a surface (animate or inanimate) infected with MRSA. The microbial reduction assays are described in the Examples below. The bactericidal efficacy of the foamable compositions was determined from the MRSA kill rate.
  • drug resistance refers to the ability of a microorganism to withstand the effects of a drug.
  • Antibiotic resistance refers to a specific type of drug resistance in which the microorganism is able to withstand the effects of an antibiotic. Antibiotic resistance may evolve naturally or artificially. Bacteria that have developed resistance to a certain antibiotic are referred to as “drug resistant bacteria.” If a bacteria is resistant to several different compounds and/or a class of antibiotics, it is called “multi- resistant” or “multi-drug resistant.” For example, MRSA is a multi-drug resistant strain of the bacteria Staphylococcus aureus.
  • antimicrobial resistance refers to the ability of a microorganism to withstand an antimicrobial substance.
  • drug resistant strains have been reported for numerous microbes in addition to Staphylococcus spp., including but not limited to, Enterococcus spp., Streptococcus spp., Escherichia spp., Mycobacterium spp., Salmonella spp., Campylobacter spp., Acinetobacter spp., Saccharomyces spp., Candida spp., Cryptococcus spp., and Pseudomonas spp.
  • the abbreviation spp. is used to mean species in the designated genus.
  • natural essential oils that have not been refined or adulterated contain non-principal constituents that contribute to the environmental and human health and safety profiles of the compositions, including their antimicrobial properties. As the mechanism of antimicrobial activity is most often unknown for natural essential oils, additional refining beyond the extraction from a plant source of natural whole oil may modify the environmental and health and safety profiles of the essential oil in a negative fashion and possibly promote microbe resistance.
  • Natural essential oils are used as the sole or principal antimicrobial agents in the foamable compositions described herein.
  • thyme oil and/or origanum oil are used as natural antimicrobial agents in the foamable compositions.
  • thyme oil as the sole or principal antimicrobial component includes the essential oil of thyme and all of its naturally- occurring constituents, thymol and thymol derivatives.
  • Thymol The main chemical components of natural thyme oil extracted from Thymus vulgaris include ⁇ -thujone, ⁇ -pinene, camphene, ⁇ -pinene, p-cymene, ⁇ -terpinene, linalool, borneol, terpinen-4-ol, ⁇ -caryophyllene, thymol, and carvacrol. Thymol and carvacrol are monoterpene phenol compounds. Thymol is the principal component of natural thyme oil. Generally, natural thyme oil, on average, has approximately 35-40% thymol and thymol derivatives, and about 3% to about 7% carvacrol and carvacrol derivatives. Representative herbs from which thyme oil may be obtained include, but are not limited to, Thymus vulgaris, Thymus serpyllium, Thymus capitatus, Thymus mastichina and Thymus zygus.
  • Natural origanum oil generally has about 60% carvacrol and carvacrol derivatives, and about 3% to about 7% thymol and thymol derivatives.
  • the phenolic compounds ⁇ e.g., thymol and thymol derivatives) present in origanum oil can also provide antimicrobial activity.
  • Representative herbs from which origanum oil may be obtained include, but are not limited to, Origanum vulgar and Origanum dictamnus.
  • the foamable composition contains an antimicrobial amount of thyme oil.
  • the amount can be about 0.01% w/v to about 0.5% w/v, about 0.01% w/v to about 0.2% w/v, about 0.01% w/v to about 0.05% w/v, or, in an especially preferred embodiment about 0.016% w/v thyme oil.
  • the foamable composition further comprises botanical thymol crystals.
  • the amount can be about 0.01% w/v to about 0.5% w/v, about 0.01% w/v to about 0.1% w/v, or about 0.032% w/v.
  • the foamable composition further comprises origanum oil.
  • the amount can be about 0.01% w/v to about 0.2% w/v, about 0.01% w/v to about 0.05% w/v, or in an especially preferred embodiment about 0.016% w/v.
  • the foamable compositions described herein contain one or more surfactants, e.g., an alkyl polyglucoside surfactant.
  • the alkyl polyglucoside surfactants when mixed with the essential oils and water, help to form a stable macroemulsion or microemulsion of the foamable composition.
  • the foamable compositions can contain an alkyl polyglucoside surfactant in an amount of about 0.01% v/v to about 10% v/v, about 0.5% v/v to about 8% v/v, or in an especially preferred embodiment about 2% v/v.
  • alkyl polyglucosides include capryl glucoside (Glucopon® 215CS UP), decyl glucoside (Glucopon®225DK), coco-glucoside (Glucopon® 425-N), lauryl glucoside (Glucopon® 625 UP), an aqueous solution of alkyl polyglucosides based on fatty acid alcohol C9-C11 (APG® 325N), and sodium laureth sulfate & lauryl glucoside & cocoamidopropyl betaine (Plantapon® 611L).
  • capryl glucoside Glucopon® 215CS UP
  • decyl glucoside Glucopon®225DK
  • coco-glucoside Glucopon® 425-N
  • lauryl glucoside Glucopon® 625 UP
  • an aqueous solution of alkyl polyglucosides based on fatty acid alcohol C9-C11 APG® 325N
  • the alkyl polyglucoside surfactant is a sulfonated surfactant, which renders the surfactant anionic.
  • a sulfonated alkyl polyglucoside surfactant include sodium decylglucosides hydroxypropyl sulfonate (Suga®Nate 100), sodium decylglucosides hydroxypropyl sulfonate and sodium laurylglucosides hydroxypropyl sulfonate (Suga®Nate 124), and sodium laurylglucosides hydroxypropyl sulfonate Suga®Nate 160 (Suga®Nate 160).
  • alkyl polyglucoside surfactants e.g., a sulfonated alkyl polyglucoside
  • alkyl polyglucoside surfactants display excellent foaming characteristics and cause low to no irritation to the skin and eyes. Consequently, a foam comprising a non-irritating surfactant, such as an alkyl polyglucoside, may allow for improved treatment of wounds.
  • the foamable composition described herein contains a source of divalent copper ions.
  • Sources of divalent copper ions include, but are not limited to, cupric salts and copper salts such as copper sulfate, copper chloride, copper nitrate, copper acetate, cupric carbonate, cupric acetate, cupric citrate, cupric potassium chloride, cupric bromide, cupric chloride, cupric fiuroborate, cupric hydroxide, cupric nitrate, cupric oxide, and cupric sulfide. Copper peptide complexes are also a source of divalent copper ions.
  • the source of divalent copper ions may be a copper peptide complex.
  • the copper peptide complex can be present in an amount of from about 0.001% w/v to about 0.5% w/v, about 0.005% w/v to about 0.05% w/v, or in a preferred embodiment about 0.008% w/v.
  • Copper peptides are small fragments of protein that have an affinity for copper.
  • the peptide of the complex may comprise amino acids in the naturally occurring L- configuration, the D-configuration, or a mixture of D- and L-amino acids.
  • the ratio of peptide molecule to copper may be either 1 :1 or 2 : 1.
  • Copper peptides may contribute to tissue regeneration, and in particular, the healing of wounds and skin lesions. Importantly, recent studies have suggested that copper peptides may reduce or eliminate various forms of skin irritation. See, Prickart, L., Skin Remodeling with Copper Peptides. Cosmetics and Medicine ( Russian), 2004. Consequently, a foamable composition comprising a copper peptide complex may improve treatment of open wounds.
  • Non-limiting examples of copper peptide complexes include glycyl-histidyl-lysine:copper (aka copper PCA), glycyl-(3-methyl)histidyl-lysine:copper, alanyl-histidyl-lysinexopper, alanyl- (3-methyl)histidyl-lysine:copper, glycyl-histidyl-phenylalanine:copper, glycyl-(3- methyl)histidyl-phenylalanine:copper, alanyl-histidyl-phenylalanine:copper, alanyl-(3- methyl)histidyl-phenylalanine:copper, glycyl-histidyl-lysyl-phenylalanyl- phenylalanyl: copper, glycyl-histidyl-ly
  • the foamable composition comprises copper PCA. Combinations of any of the foregoing and other copper peptide complexes may be used.
  • the foamable composition may be optionally provided as a concentrate wherein the amount of carrier present in the composition is reduced. For example, the amount of water present in the composition may be reduced.
  • the concentrated composition may be reconstituted as desired by the addition of water at the time of use.
  • the concentrated composition may be provided as about a 1 : 10, 1 :50, or 1 : 100 concentrate, for example.
  • the foamable composition may optionally include one or more other ingredients to improve the aesthetic or other beneficial properties.
  • Such optional ingredients may include fragrances, deodorizers, coloring agents, degreasing compounds, penetration enhancers, or any other inactive ingredient commonly used in topical cosmetics or pharmaceuticals. These optional ingredients, however, should be compatible with the core components of the antimicrobial foamable composition. The addition of these optional ingredients to the foamable composition should not negatively affect the efficacy or the environmental and human health and safety profiles of the foamable composition.
  • the foamable composition may further comprise at least one fragrance.
  • the fragrance can be present in an amount of about 0.01% v/v to about 5.0% v/v, about 0.01% v/v to about 1.0% v/v, or about 0.01% v/v to about 0.5% v/v.
  • a fragrance include vanilla, lavender, rose, rosemary, violet leaf, ginger, bergamot, spearmint, mint, eucalyptus, lime, blood orange, tangerine, grapefruit, lemon, lemongrass, petitgrain, litsea cubeba, pine, cedarwood, rosewood, chamomile, magnolia, and geranium.
  • the foamable composition includes one or more of: blood orange, vanilla, lavender, ginger, bergamot, spearmint, and lime.
  • the foamable compositions described herein differ from other soap products that include thyme oil merely as a fragrance.
  • the unique formulation of the thyme oil foamable compositions described herein achieve antimicrobial activity.
  • the foamable compositions achieve high antimicrobial activity with low levels of thyme oil.
  • the thyme oil in combination with particular glucoside surfactants provide a very effective antimicrobial composition, particularly when used to kill MRSA.
  • the foamable compositions may further comprise at least one antioxidant.
  • the antioxidant can be present in an amount of about 0.001% v/v to about 0.5% v/v, about 0.001% v/v to about 0.1% v/v, or about 0.008% v/v to about 0.01% v/v.
  • Antioxidants are molecules that neutralize free radicals in the body. Free radicals are a natural product of standard reactions within the cell and are important in many biological processes. However, free radicals can also damage cells and cause abnormal cellular function (e.g., collagen breakdown). Antioxidants may help prevent the damage that is caused by exposure to free radicals. In addition, antioxidants may also help stimulate the production of collagen fibers which is essential to maintaining and repairing the skin.
  • Non-limiting examples of an antioxidant include white tea extract, green tea extract, GHK copper peptides (e.g., copper PCA), vitamin C (L-ascorbic acid), grape seed extract, marine algae (e.g., Haematococcus algae), vitamin E, lycopene, bioflavanoids, blueberry extract, blackberry extract, pomegranate extract, beta carotene, idebenone, and coenzyme QlO.
  • the foamable comprises white tea extract and/or copper PCA.
  • the foamable composition may further comprise a natural moisturizer.
  • the natural moisturizer can be present in an amount of about 0.01% v/v to about 5.0% v/v, about 0.05% v/v to about 1.0% v/v, or about 0.1% v/v.
  • the natural moisturizer can be, e.g., a humectants that is mild and non-irritating.
  • Non-limiting examples of suitable moisturizers include hydrolyzed wheat protein and hyaluronic acid (Cromoist® WHYA), hydrolyzed oats (Cromoist® O- 25), hydrolyzed wheat protein and hydrolyzed wheat starch (Cropeptide® W), hydrolyzed silk (Crosilk® 10,000), silk amino acids (Crosilk® Liquid), Cocodimonium hydroxypropyl silk amino acids (Crosilkquat®), collagen amino acids (Crotein® CAA/SF), hair keratin amino acids and sodium chloride (Crotein® HKP), keratin amino acids (Crotein® HKP/SF), collagen amino acids (Crotein® MCAA), hydrolyzed milk protein (Hydrolactin® 2500), hydrolyzed soy protein (Hydrosoy® 2000), hydrolyzed wheat protein (Hydrotriticum® 2000), wheat amino acids (Hydrotriticum® WAA), and hydrolyzed
  • the foamable composition may further comprise aloe vera extract.
  • the aloe vera extract can be present in an amount of about 0.1% v/v to about 5.0% v/v, about 0.1% v/v to about 1.0% v/v, or about 0.25% v/v aloe vera extract.
  • Aloe vera is useful for treating skin conditions because it can reduce inflammation and pain to promote wound healing, and moisturize to treat dry skin conditions.
  • aloe vera may also be a source of antioxidants useful in promoting and maintaining healthy skin as discussed above.
  • the foamable composition may further comprise at least one co-surfactant.
  • the co-surfactant can be present in amount of about 0.1% v/v to about 10% v/v, about 0.5% v/v to about 8% v/v, or about 5% v/v.
  • the co-surfactant further helps to solubilize and disperse the essential oil(s) in water.
  • the co-surfactants may be anionic, cationic, zwitteronic, or nonionic surfactants.
  • Non-limiting examples of suitable co-surfactants include sodium laurel ether sulphate, sodium laurel sulphate, sodium lauryl sulfate, sarcosinates, yucca, naturally-derived sulfosuccinate, betaine, sultaine, propionate, acetate, amine oxide, naturally-derived ammonium chloride, geminis, carboxylate, and alcohol ethoxylate.
  • the co-surfactant is a biobased surfactant, which is a surfactant that is not principally derived from a petrochemical feedstock.
  • the foamable composition preferably employ water as a carrier.
  • the pH of the foamable composition is in a range of about 0.2 to about 8.0, most preferably the pH is the range of about 3.5 to about 6.
  • the composition may further comprise at least one pH modifying agent, such as citric acid or sodium citrate.
  • the pH modifying agent can be present in an amount of about 0.1% w/v to about 5% w/v, about 0.1% w/v to about 0.5% w/v, about 0.4% w/v, or about 0.2% w/v.
  • the foamable compositions described herein may be classified by the FDA as an over-the-counter antiseptic drug product.
  • An "antiseptic” is defined by the FDA as a product that is used to prevent infection by killing or inhibiting the growth of microorganisms.
  • Antiseptics include "consumer antiseptics,” which are defined by the FDA as a class of antimicrobial drug products marketed or proposed for use by the general public in a variety of settings. Consumer antiseptics include antibacterial soaps, hand sanitizers, and antibacterial wipes.
  • “Healthcare antiseptics” are products used in a hospital or healthcare setting, where the risk of infection is greater.
  • Healthcare antiseptics include handwashes, preoperative skin preparations, surgical hand scrubs, and hand sanitizers for use primarily in hospitals, clinics, doctor's offices, outpatient setting, nursing homes, and the like.
  • the 1994 FDA Tentative Monographs propose that both consumer and healthcare personnel antiseptics achieve the efficacy criteria of 2 logio bacterial reduction after the first use.
  • the antimicrobial foamable compositions described herein have demonstrated efficacy greater than the standards for both consumer and healthcare products as proposed in the most current FDA monograph (1994) ⁇ see Example 1, Table 3; Example 2, Table 5; Example 3, Table 7).
  • the foamable composition may also be used to treat a number of other skin infections, including, but not limited to, impetigo, folliculitis, boils, ecthyma, erysipelas, cellulitis, jock itch, acne, and athlete's foot.
  • Many current acne treatment use harsh chemicals ⁇ e.g., salicylic acid) that can irritate skin.
  • the foams described herein are a gentle, natural, and effective product for treating or preventing acne.
  • the foamable compositions may also be useful as an antimicrobial substance to prevent or treat microbial infections of other tissues including the rectum, vagina, penile urethra, mucosal membranes, and oral cavity.
  • the foamable composition may be used as a "therapeutic bandage" wherein the composition is applied to the skin and allowed to spread and/or cover the affected area. Microbes often enter the body through a wound, resulting in a more serious infection.
  • a wound refers to an injury to the skin, tissue, or external surface of the body often as a result of physical trauma that causes disruption of the normal continuity of structure.
  • an "open wound” refers to a type of wound in which in the skin is torn, cut, pierced, punctured, or otherwise impaired so as to expose the injury and the underlying tissue. An open wound is at high risk for infection.
  • Staph and MRSA infections are often associated with entry into the body through a wound ⁇ e.g., as a result of injury or surgery).
  • the foamable composition may be less irritating to wounds, thus improving patience compliance and maximizing the therapeutic effect.
  • a mechanical force e.g., rubbing the composition onto the surface
  • the foam freely spreads on the surface and is rapidly absorbed.
  • the foam may be useful to prevent and/or treat secondary infections accompanying skin structure damage, such as in cuts, wounds, burns, and lesions.
  • the antimicrobial foamable composition is easy to use and spreads easily, covering the affected area without causing pain.
  • the antimicrobial foamable composition may removed ⁇ e.g., wiped or rinsed) from the surface after application. Alternatively, the foam may be left on the surface following application.
  • the foamable composition may be applied to mammalian skin, more preferably to human skin. Sustained contact with the area bearing the microorganisms may ensure a higher killing rate and continuous germ control for extended periods of time. Further, since the foamable compositions do not require wiping or rinsing to remove any antimicrobial residues, the present compositions are convenient and easy to use. In some instances, it may be desirable to cover the application area with a sterile bandage or gauze.
  • the composition may be applied to the skin and/or wound infected with MRSA and covered with a sterile bandage.
  • the foam may first be applied to a bandage, gauze, or other applicator that is subsequently contacted to the skin and/or wound.
  • the bandage in combination with the foamable composition may function to further protect the infected area.
  • the foamable compositions are preferably alcohol-free and preferably do not contain synthetic chemicals commonly found in cosmetics and pharmaceuticals (e.g., petrochemicals and parabens). Further, the compositions are non-corrosive, non-flammable, non-reactive, readily biodegradable, and have a very low volatile organic compound level of less than 1%.
  • the foamable composition may be topically applied for a duration of seconds to hours.
  • the foam may remain in contact with the surface (i.e., exposure time) about 15 seconds to about 300 seconds, about 5 minutes to about 60 minutes, about one hour to about 24 hours, or longer.
  • Adequate exposure time may result in at least 99.9% of microbes killed in 15 seconds. More preferably, after an exposure time of 15 seconds, 99.99% of MRSA was killed. (See Example 2, Table 5 and Example 3, Table 7).
  • the foamable composition may be applied one or more times a day (e.g., once a day, twice a day, three times a day) or as needed.
  • the foam can be applied directly to the surface, such as the skin and/or wound.
  • One or more additional products may be co-administered, either within the foamable composition or separately administered.
  • the foam may be coadministered with another antimicrobial or antibacterial product, a topical analgesic, or an antipyretic.
  • an antimicrobial product include clindamycin, salicylic acid, gramicidin, neomycin, and polymyxin.
  • a topical analgesic include capsaicin, lidocaine, and methyl salicylate.
  • the particular combination of components used in the foamable compositions provides a stable composition.
  • the foams will have a shelf life of at least 2 years.
  • the foamable composition may be formulated by conventional procedures known in the art.
  • the foamable composition can be formulated by combining thyme oil, an alkyl polyglucoside surfactant, and water together. The combined ingredients are then agitated or mixed until a macroemulsified or microemulsified solution of thyme oil is formed.
  • Risk factors for healthcare-associated versus community-associated MRSA may differ due to the different settings.
  • Risk factors for HA-MRSA include visiting a hospital or long-term care facility as a visitor, patient, resident, or worker.
  • Individuals who are on dialysis, are catheterized, or have feeding tubes or other invasive devices (e.g., catheters and intravenous lines) are more likely to develop a MRSA infection.
  • Older adults (about 65 years of age or older) or individuals with weakened immune systems, burns, surgical wounds, or serious underlying health problems that are hospitalized are also at increased risk for infection with HA-MRSA.
  • the main risk factors for CA-MRSA include age, participating in contact sports, sharing towels or athletic equipment, a weakened immune system, living in crowded or unsanitary conditions, and association with healthcare workers.
  • CA-MRSA can be particularly dangerous in children (up to about 16 years of age), because they are more likely to develop dangerous forms of pneumonia than adults.
  • those individuals with weakened immune systems, such as children and individuals infected with HIV/AIDS may be more likely to develop severe MRSA infections.
  • CA-MRSA outbreaks have been reported in public gyms as well as among both amateur and professional sports teams.
  • outbreaks of CA-MRSA have occurred in military training camps.
  • An individual who has one or more of these risk factors for CA-MRSA or HA-MRSA is at increased risk for developing MRSA infection, and may benefit from the antimicrobial foamable compositions of the present invention.
  • the foamable composition may be formulated to be dispersed from a dispenser, such as a pump or a bottle.
  • the dispenser may be manual or automatic, such that the dispenser may be a hands-free dispenser that provides an amount of foam without having to press a button, lever, etc. thereby further minimizing the spread of bacteria and other microbes.
  • Exemplary locations for a foamable composition dispenser include, without limitation, homes, schools, gyms, hospitals, long-term care facilities, day care facilities, dormitories, and military camps.
  • the foamable composition should be of a consistency as to allow it to flow through the dispenser, such that air bubbles can be trapped, and an acceptable foam produced.
  • the quality of the foam may include a rich and creamy appearance, very small bubble size, and the ability to retain creaminess upon spreading on the skin such that it does not become watery.
  • Numerical ranges recited herein include all circumscribed ranges i.e., those where the upper and lower values of such ranges are numbers that fall within the broad range.
  • Antimicrobial foamable compositions were prepared, having ingredients in the amount by volume (% v/v) specified below.
  • Formulations of the foamable composition Four formulations of the foamable composition were prepared having the ingredients specified in Table 1 below.
  • a suspension of bacterial cells was exposed to the test substance for specified contact times. After exposure, an aliquot of the suspension was transferred to a neutralizer and assayed for survivors. Appropriate purity, sterility, microorganism population and neutralization controls were performed.
  • test organisms were Community Acquired Methicillin Resistant Staphylococcus aureus - CA-MRSA (NRS384) (Genotype USA300) or Staphylococcus aureus - MRSA (ATCC 33592).
  • the test organisms were purchased from the NARSA Contracts Administrator or the American Tissue Type Culture Collection (ATCC), respectively, by ATS Labs.
  • Inoculum Preparation Using a stock culture of the test organism, a culture of the test organism was streaked onto the culture medium of tryptic soy agar containing 5% sterile sheep blood. The bacterial cultures were incubated for 24 - 48 hours at 35-37 0 C (alternate or extended incubation may be required for certain strains). A sufficient amount of organism growth was transferred into a sterile diluent to yield a uniform suspension of approximately 1x10 8 CFU/mL. (CFU is colony forming unit.) Most bacterial strains approximately matched a 0.5 McFarland standard. Cultures were further adjusted as needed. Antimicrobial susceptibility testing was performed utilizing a representative culture from the day of testing to verify the antimicrobial resistance pattern stated.
  • test substance was prepared according to the directions supplied. A 9.9 mL aliquot of the prepared test substance was transferred to a sterile vessel ⁇ e.g., glass tube, stomacher bag, etc.) for testing procedures. The test substance was used within 3 hours of preparation if additional preparation was required by ATS Labs.
  • Test Substance Exposure A 0.1 mL aliquot of the standardized inoculum was added to the test substance representing the start of the test exposure. The inoculated test substance was immediately mixed thoroughly using a laboratory stomacher, vortex mixer or other applicable method. The inoculated and mixed test substance was held at the specified temperature. If the requested exposure temperature lies outside of achievable ambient conditions, the test substance was equilibrated in a water bath (or other appropriate device) to equilibrate to the desired exposure temperature. An inoculum of 0.1 mL of the organism suspension was added to 9.9 mL of the test substance and vortex mixed. The test mixture was exposed for 15, 30, 60, 120 and 300 seconds at ambient temperature (21 0 C).
  • Subculture At each specified exposure time, a 1.0 mL aliquot of the inoculated est substance was transferred to 9 mL of neutralizer broth. Four additional 1 :10 dilutions in Butterfield's Buffer were prepared. Using a standard microbiological spread plate count procedure, 1.0 mL aliquots of each dilution (10 ⁇ 10 -10 4 ) were plated in duplicate to the appropriate recovery media. A 5.0 mL aliquot of the neutralized sample was transferred to a sterile 0.45 ⁇ m filter apparatus system pre- wetted with 10 mL sterile diluent ⁇ e.g., 0.85% sterile saline). The sample was filter concentrated and the filter rinsed using >50 mL sterile diluent ⁇ e.g., 0.85% sterile saline). The filter was aseptically removed and placed on the surface of the recovery agar medium.
  • Test Population Control In a similar manner as the culture inoculum was added to the test substance, an equivalent volume (0.1 mL) of each inoculum was added to 9.9 mL of Butterf ⁇ eld's (same volume as the test substance). This suspension was neutralized as in the test procedure. This suspension was serially diluted and appropriate dilutions were plated using standard microbiological techniques. Following incubation, the organism plates were observed to enumerate the concentration of the test organism present in the test substance at the time of testing (time analysis). The acceptance criterion for this study control is growth and the value is used for calculation purposes only.
  • Purity Control A streak plate for isolation was performed on the organism culture. Following incubation, they were examined to confirm the presence of a pure culture. The acceptance criterion for this study control is a pure culture demonstrating colony morphology typical of the test organism.
  • Test Data CFU/mL (avg. # colonies found/plate (a), dilution used)(dilution factorK volume neutralized solution)
  • the above described methodology is an example which may be adapted for testing the efficacies of the antimicrobial product as required by governing agencies.
  • the examples below were carried out using standard, peer-reviewed methods developed by the American Society for Testing and Materials (ASTM).
  • ASTM methodology has been proposed as the FDA standard for efficacy in the Final Monograph for over-the-counter antibacterial drugs.
  • the foamable composition of Formulation 1 demonstrated a 99.9% (3.735 Logio) reduction of Community Acquired Methicillin Resistant Staphylococcus aureus - CA-MRSA (NARSA NRS384) (Genotype USA300) survivors after a 15 second exposure, a 99.999% (5.2 Logio) reduction after a 30 second exposure, a > 99.999% (> 5.8 Logio) reduction after a 60 second exposure, a > 99.999% (> 5.8 Logio) reduction after a 120 second exposure and a > 99.999% (> 5.8 Logio) reduction after a 300 second exposure when tested at ambient temperature (21 0 C).
  • Example 2 Time Kill Test Assay against MRSA [0082] Under the conditions of this study, the foamable composition of Formulation 1 demonstrated a 99.99% (4.32 Logio) reduction of Staphylococcus aureus - MRSA survivors after a 15 second exposure, a 99.999% (5.5 Logio) reduction after a 30 second exposure, a >99.999% (>5.8 Logio) reduction after a 60 second exposure, and a > 99.999% (> 5.8 Logio) reduction after a 300 second exposure in the presence of a 5% fetal bovine serum organic soil load when tested at ambient temperature (20 0 C).
  • the foamable composition of Formulation 3 demonstrated a 99.99% (4.84 Logio) reduction of Staphylococcus aureus - MRSA survivors after a 15 second exposure, a > 99.999% (> 5.8 Logio) reduction after a 30 second exposure, a > 99.999% (>5.8 Logio) reduction after a 60 second exposure, and a > 99.999% (> 5.8 Logio) reduction after a 300 second exposure in the presence of a 5% fetal bovine serum organic soil load when tested at ambient temperature (20 0 C).
  • the foamable composition of Formulation 2 demonstrated a > 99.999% (> 5.9 LoglO) reduction of Staphylococcus aureus - MRSA survivors after a 30, 60, 120 and 300 second exposure when tested at ambient temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Pest Control & Pesticides (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2009/062527 2008-10-30 2009-10-29 Antimicrobial foamable soaps WO2010059366A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2742285A CA2742285A1 (en) 2008-10-30 2009-10-29 Antimicrobial foamable soaps
KR1020117011873A KR101757935B1 (ko) 2008-10-30 2009-10-29 항균성 발포 비누
US13/126,628 US20110206790A1 (en) 2008-10-30 2009-10-29 Antimicrobial Foamable Soaps
MX2011004539A MX2011004539A (es) 2008-10-30 2009-10-29 Jabones espumables antimicrobianos.
EP09827969.8A EP2350252A4 (en) 2008-10-30 2009-10-29 ANTIMICROBIAL FOAMABLE SOAPS
AU2009317951A AU2009317951B2 (en) 2008-10-30 2009-10-29 Antimicrobial foamable soaps
BRPI0920972A BRPI0920972A8 (pt) 2008-10-30 2009-10-29 sabonetes antimicrobianos espumáveis
JP2011534753A JP5782603B2 (ja) 2008-10-30 2009-10-29 抗菌発泡性石鹸
CN2009801537618A CN102317429A (zh) 2008-10-30 2009-10-29 抗微生物可发泡皂
ZA2011/03129A ZA201103129B (en) 2008-10-30 2011-04-28 Antimicrobial foamable soaps
IL212612A IL212612A0 (en) 2008-10-30 2011-05-01 Antimicrobial foamable soaps

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10972108P 2008-10-30 2008-10-30
US61/109,721 2008-10-30

Publications (2)

Publication Number Publication Date
WO2010059366A2 true WO2010059366A2 (en) 2010-05-27
WO2010059366A3 WO2010059366A3 (en) 2010-08-05

Family

ID=42198737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/062527 WO2010059366A2 (en) 2008-10-30 2009-10-29 Antimicrobial foamable soaps

Country Status (13)

Country Link
US (1) US20110206790A1 (es)
EP (1) EP2350252A4 (es)
JP (1) JP5782603B2 (es)
KR (1) KR101757935B1 (es)
CN (2) CN105112177A (es)
AU (1) AU2009317951B2 (es)
BR (1) BRPI0920972A8 (es)
CA (1) CA2742285A1 (es)
IL (1) IL212612A0 (es)
MX (1) MX2011004539A (es)
SG (1) SG2014007488A (es)
WO (1) WO2010059366A2 (es)
ZA (1) ZA201103129B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500818A (ja) * 2011-12-06 2015-01-08 ユニリーバー・ナームローゼ・ベンノートシヤープ 表面を消毒する方法
US9693941B2 (en) 2011-11-03 2017-07-04 Conopco, Inc. Liquid personal wash composition
IT201700039351A1 (it) * 2017-04-10 2018-10-10 Aboca Spa Societa Agricola Miscela antimeristematica e antigermogliante

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105112177A (zh) 2008-10-30 2015-12-02 可俐唯尔有限公司 抗微生物可发泡皂
US20140242157A1 (en) * 2009-05-05 2014-08-28 Cacao Bio-Technologies, Llc Epicatechin compositions and methods
WO2013063102A1 (en) * 2011-10-28 2013-05-02 TaylorBaby, LLC Flavored wipe and dispensing system
CN102827712B (zh) * 2012-09-21 2014-01-22 天津宏竹科技发展有限公司 一种天然环保厨房清洁剂及其制作方法
JP2014091815A (ja) * 2012-11-06 2014-05-19 Kao Corp 洗浄剤組成物
US9701886B2 (en) * 2013-03-05 2017-07-11 Halliburton Energy Services, Inc. Alkyl polyglycoside derivative as biodegradable foaming surfactant for cement
US9750245B2 (en) 2013-03-08 2017-09-05 Laboratoire M2 Topical use of an antimicrobial formulation
US10285954B2 (en) 2013-03-08 2019-05-14 Laboratoire M2 Topical use of an antimicrobial formulation
CN103627545A (zh) * 2013-11-27 2014-03-12 许伟 一种防虫肥皂
AU2015234234B2 (en) * 2014-03-17 2020-04-30 Global Bioprotect Ip Pty Ltd Antimicrobial sanitizer compositions and their use
WO2016063265A2 (pt) * 2014-10-24 2016-04-28 Palmeira De Oliveira Rita Manuela Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos
MA41021A (fr) * 2014-11-25 2017-10-03 Cms Tech Inc Compositions antimicrobiennes à base de cuivre et leur utilisation dans le traitement de produits alimentaires et de surfaces
JP7033125B2 (ja) * 2016-06-02 2022-03-09 ワイピング システムズ エイピーエス 酒石酸および乳酸を含む殺菌組成物
KR101883720B1 (ko) 2016-12-30 2018-07-31 대구보건대학교 산학협력단 천연자원을 이용한 항균 비누 조성물
MX2020006279A (es) * 2017-12-21 2020-09-17 Unilever Ip Holdings B V Composición limpiadora biocida de acción rápida.
CN109957467A (zh) * 2017-12-25 2019-07-02 浙江神英科技有限公司 一种杀菌内衣洗衣液
CN109055053A (zh) * 2018-10-11 2018-12-21 山东中医药大学 一种地椒手工皂及其制备方法
EP4017263A4 (en) * 2019-08-22 2023-08-16 Botanohealth Ltd MUCILAGE-BASED PLANT PROTECTION PRODUCT AND METHOD THEREOF
CN110484376A (zh) * 2019-09-12 2019-11-22 贵州沐木皙颜生物科技有限公司 一种白茶氨基酸纳米透明皂及其加工方法
KR102266094B1 (ko) * 2020-12-01 2021-06-17 (주)다래월드 친환경 세정제 조성물 및 이를 포함하는 세정제
KR102335588B1 (ko) * 2021-03-23 2021-12-06 주식회사 케미슈티칼 구연산동을 유효성분으로 포함하는 항균성 수분산 조성물
CN114933940B (zh) * 2022-05-26 2024-03-01 九江学院 一种抑菌肥皂及其制备方法
EP4349175A1 (en) * 2022-10-05 2024-04-10 The Procter & Gamble Company Antimicrobial composition comprising a modified alkyl glycoside and an organic acid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
US5403587A (en) * 1993-04-22 1995-04-04 Eastman Kodak Company Disinfectant and sanitizing compositions based on essential oils
JP3716276B2 (ja) * 1996-09-13 2005-11-16 有限会社西清 ヒノキチオール水溶液の製造方法
BR0014778A (pt) * 1999-10-19 2002-07-16 Procter & Gamble Composição antimicrobiana, processos para matar bactérias, para desativar vìrus, para aperfeiçoar a saúde global de um mamìfero, para reduzir a ausência de pessoas, utilização de composição, produto antimicrobiano e conjunto de tratamento pessoal antimicrobiano
JP2001152189A (ja) * 1999-11-30 2001-06-05 Japan Science & Technology Corp 住宅用防カビ洗浄液組成物
US6346281B1 (en) * 2000-05-05 2002-02-12 Scentsible Life Products, A Division Of Laid Back Designs Ltd. Antimicrobial composition formulated with essential oils
JP4342761B2 (ja) * 2001-04-17 2009-10-14 花王株式会社 殺菌剤組成物
US20030148927A1 (en) * 2001-10-05 2003-08-07 Procyte Corporation Stable solutions of peptide copper complexes and cosmetic and pharmaceutical formulations produced therefrom
AU2007267823A1 (en) * 2006-06-01 2007-12-06 Sakura Properties, Llc Fucoidan compositions and methods
US8147877B2 (en) * 2006-06-01 2012-04-03 Ohso Clean, Inc. Essential oils based disinfecting compositions having tuberculocidal and fungicidal efficacies
US7465697B1 (en) * 2006-11-02 2008-12-16 Ohsoclean, Inc. Essential oils based cleaning and disinfecting compositions
CA2720738C (en) 2008-04-08 2014-10-07 Laboratoire M2 Disinfectant formulation
CN105112177A (zh) 2008-10-30 2015-12-02 可俐唯尔有限公司 抗微生物可发泡皂
JP2014125435A (ja) 2012-12-25 2014-07-07 Kracie Home Products Ltd 皮膚洗浄剤組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2350252A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9693941B2 (en) 2011-11-03 2017-07-04 Conopco, Inc. Liquid personal wash composition
JP2015500818A (ja) * 2011-12-06 2015-01-08 ユニリーバー・ナームローゼ・ベンノートシヤープ 表面を消毒する方法
IT201700039351A1 (it) * 2017-04-10 2018-10-10 Aboca Spa Societa Agricola Miscela antimeristematica e antigermogliante
WO2018189610A1 (en) * 2017-04-10 2018-10-18 Aboca S.P.A Società Agricola Anti-sprouting mixture comprising essential oils

Also Published As

Publication number Publication date
EP2350252A2 (en) 2011-08-03
CN105112177A (zh) 2015-12-02
KR101757935B1 (ko) 2017-07-14
SG2014007488A (en) 2014-04-28
JP2012507549A (ja) 2012-03-29
BRPI0920972A8 (pt) 2019-02-05
JP5782603B2 (ja) 2015-09-24
AU2009317951A1 (en) 2010-05-27
KR20110133467A (ko) 2011-12-12
WO2010059366A3 (en) 2010-08-05
US20110206790A1 (en) 2011-08-25
ZA201103129B (en) 2012-10-31
CN102317429A (zh) 2012-01-11
EP2350252A4 (en) 2013-09-25
AU2009317951B2 (en) 2014-07-31
MX2011004539A (es) 2011-09-28
IL212612A0 (en) 2011-07-31
CA2742285A1 (en) 2010-05-27
BRPI0920972A2 (pt) 2016-01-05

Similar Documents

Publication Publication Date Title
AU2009317951B2 (en) Antimicrobial foamable soaps
CA2562329C (en) Therapeutic antimicrobial compositions and methods
CN101489379B (zh) 抗微生物组合物
US9050288B2 (en) Cleanser compositions and methods for using the same
US6383523B1 (en) Pharmaceutical compositions and methods for managing skin conditions
US9814737B2 (en) Composition for skin sanitization and protection and method of its use
US6413921B1 (en) Antimicrobial composition containing parachlorometaxylenol (PCMX)
WO2018087766A1 (en) Topical compositions for the treatment of acne
WO2008061375A1 (en) Antiseptic
US20190105343A1 (en) Treatment of Skin Conditions and Diseases Associated with Microbial Biofilms
CA3143518A1 (en) Compositions and methods for the antiseptic cleansing and biofilms treatment of mammalian tissue
AU2013289294B2 (en) Use of zinc coceth sulfate as an antibacterial agent against Propionibacterium acnes
Hall et al. A comparison of the antibacterial efficacy and cytotoxicity to cultured human skin cells of 7 commercial hand rubs and Xgel, a new copper-based biocidal hand rub
Gor et al. Formulation and physicochemical evaluation of polyherbal acne soap using selected medicinal plants
Fahad et al. Preparation and studying of the physiochemical properties and antimicrobial activity of new triple-action glass cleaners
US20230126284A1 (en) Antiseptic compositions
RU2409367C2 (ru) Средство для кожи профилактическое с противотуберкулезным эффектом
WO2022203538A1 (ru) Биологически активный квадрокомплекс для регуляции биоразнообразия микробиоты кожи
WO2022123313A1 (en) Skin sanitizing compositions containing manuka oil

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980153761.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09827969

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13126628

Country of ref document: US

Ref document number: 2011534753

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2742285

Country of ref document: CA

Ref document number: 2009317951

Country of ref document: AU

Ref document number: MX/A/2011/004539

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 212612

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009827969

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117011873

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009317951

Country of ref document: AU

Date of ref document: 20091029

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2229/KOLNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: PI0920972

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110502